Skip to main content

Prehypertension: Risk stratification and management considerations

Current Hypertension Reports volume 10, pages 359–366 (2008)Cite this article

Abstract

Approximately 37% of US adults are prehypertensive; about 31 million have blood pressures in the range of 130–139/85–89 mm Hg. These stage 2 prehypertensives have threefold greater risk for developing hypertension and twofold higher risk for cardiovascular events than normotensives. Lifestyle changes only are recommended for most prehypertensives, but evidence for community-wide effectiveness is limited. Projected numbers needed to treat to prevent a cardiovascular event are similar for stage 2 prehypertension and stage 1 hypertension when both groups are matched for concomitant risk factors. However, no clinical trials document that pharmacotherapy reduces cardiovascular events in stage 2 prehypertension. The Trial of Preventing Hypertension demonstrated that angiotensin receptor blockade safely lowers blood pressure and prevents or delays progression to hypertension in stage 2 prehypertensives. We believe it is reasonable for clinicians to identify stage 2 prehypertensives at high absolute risk for progression to hypertension and cardiovascular events, and to treat them with a renin-angiotensin system blocker when life-style changes alone are ineffective.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Robinson SC, Brucer M: Range of normal blood pressure: A statistical and clinical study of 11,383 persons. Arch Intern Med 1939, 64:409–444.

    Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, et al.: National High Blood Pressure Education Program Coordinating Committee: Seventh Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.

    Article  PubMed  CAS  Google Scholar 

  3. Greenlund KJ, Croft JB, Mensah GA: Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. Arch Intern Med 2004, 164:2113–2118.

    Article  PubMed  Google Scholar 

  4. Neaton JD, Kuller L, Stamler J, Wentworth DN: Impact of systolic and diastolic blood pressure on cardiovascular mortality. In Hypertension, Pathophysiology, Diagnosis, and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:127–144.

    Google Scholar 

  5. Levy RL, Hillman CC, Stoud WD, et al.: Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945, 129:585–588.

    Google Scholar 

  6. Julius S, Schork MA: Borderline hypertension—a critical review. J Chron Dis 1971, 23:723–754.

    Article  PubMed  CAS  Google Scholar 

  7. Julius S, Jamerson K, Mejia A, et al.: The association of borderline hypertension with target organ changes and higher coronary risk. JAMA 1990, 264:354–358.

    Article  PubMed  CAS  Google Scholar 

  8. Giles TD, Berk BC, Black HR, et al.; for the Hypertension Writing Group: Expanding the definition and classification of hypertension. J Clin Hypertens 2005, 7:505–512.

    Article  Google Scholar 

  9. Wang Y, Wang QJ: The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee Guidelines: new challenges of the old problem. Arch Intern Med 2004, 164:2126–2134.

    Article  PubMed  Google Scholar 

  10. Ostchega Y, Yoon SS, Hughes J, Louis T: Hypertension Awareness, Treatment, and Control—Continued Disparities in Adults: United States, 2005–2006. Hyattsville, MD: National Center for Health Statistics; January 2008. [NCHS data brief no. 3]

    Google Scholar 

  11. Qureshi AI, Suri MF, Kirmani JF, Divani AA: Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005, 11:CR403–CR409.

    PubMed  Google Scholar 

  12. Leitschuh M, Cuppies LA, Kannel W, et al.: High-normal blood pressure progression to hypertension in the Framingham Study. Hypertension 1991, 17:22–27.

    PubMed  CAS  Google Scholar 

  13. Winegarden CR: From “prehypertension” to hypertension? Additional evidence. Ann Epidemiol 2004, 15:720–725.

    Article  Google Scholar 

  14. Julius S, Nesbitt SD, Egan BM, et al.: Trial of Preventing Hypertension (TROPHY) Investigators: Feasibility of treating prehypertension with an angiotensin receptor blocker. N Engl J Med 2006, 354:1685–1697.

    Article  PubMed  CAS  Google Scholar 

  15. Julius S, Kaciroti N, Egan BM, et al.: TROPHY revisited: outcomes based on the JNC 7 definition of hypertension. JASH 2008, 2:39–43.

    Google Scholar 

  16. Julius S, Jamerson K, Mejia A, et al.: The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA 1990, 265:354–358.

    Article  Google Scholar 

  17. Eliasson M, Jansson JH, Nilsson P, Asplund K: Increased levels of tissue plasminogen activator antigen in essential hypertension: a population-based study. J Hypertens 1997, 15:349–356.

    Article  PubMed  CAS  Google Scholar 

  18. Toikka JO, Laine H, Ahotupa M, et al.: Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 2000, 36:929–933.

    PubMed  CAS  Google Scholar 

  19. Palombo C, Kozakova M, Magagna A, et al.: Early impairment of coronary flow reserve and increase in minimum coronary resistance in borderline hypertensive patients. J Hypertens 2000, 18:453–459.

    Article  PubMed  CAS  Google Scholar 

  20. Millgard J, Hagg A, Sarabi M, Lind L: Endothelium-dependent vasodilation in normotensive subjects with a familial history of essential hypertension and in young subjects with borderline hypertension. Blood Pressure 2002, 11:279–284.

    Article  PubMed  Google Scholar 

  21. Chrysohoou C, Pitsavos C, Panagiotakos DB, et al.: Association between prehypertension status and inflammatory markers related to atherosclerotic disease. The Attica Study. Am J Hypertens 2004, 17:568–573.

    Article  PubMed  CAS  Google Scholar 

  22. Vasan RS, Larson MG, Leip EP, et al.: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291–1297.

    Article  PubMed  CAS  Google Scholar 

  23. Liszka HA, Mainous AG, King DE, et al.: Prehypertension and cardiovascular morbidity. Ann Fam Med 2005, 3:294–299.

    Article  PubMed  Google Scholar 

  24. Kshirsagar AV, Carpenter M, Bang J, et al.: Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006, 119:133–141.

    Article  PubMed  Google Scholar 

  25. Egan BM: Should metabolic syndrome patients with prehypertension receive antihypertensive therapy? In Therapeutic Strategies in Hypertension. Edited by Bakris GL. Oxford: Clinical Publishing; 2006:9–25.

    Google Scholar 

  26. Zhang Y, Lee ET, Devereux RB, et al.: Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 2006, 47:410–414.

    Article  PubMed  CAS  Google Scholar 

  27. Hsia J, Margolis KL, Eaton CB, et al.; Women’s Health Initiative Investigators: Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007, 115:855–860.

    Article  PubMed  Google Scholar 

  28. Ogden LG, He J, Lydick E, Whelton PK: Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000, 35:539–543.

    PubMed  CAS  Google Scholar 

  29. Nesbitt SN, Julius S, Leonard D, et al.: the TROPHY Study Investigators: Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY Study. Am J Hypertens 2005, 18:979–984.

    Article  Google Scholar 

  30. Lasser VI, Raczynski JM, Stevens VJ, et al.: the Trials of Hypertension Prevention (TOHP) Collaborative Research Group: Trial of Prevention, phase II: structure and content of the weight loss and dietary sodium reduction interventions. Ann Epidemiol 1995, 5:156–164.

    Article  PubMed  CAS  Google Scholar 

  31. The Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997, 157:657–667.

    Article  Google Scholar 

  32. Hjermann I, Velve Byre K, Holme I, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981, 2:1303–1310.

    Article  PubMed  CAS  Google Scholar 

  33. Hjermann I: Smoking and diet intervention in healthy coronary high risk men. Methods and 5-year follow-up of risk factors in a randomized trial. The Oslo Study. J Oslo City Hosp 1980, 30:3–17.

    PubMed  CAS  Google Scholar 

  34. Moser M: A decade of progress in the management of hypertension. Hypertension 1983, 5:808–813.

    PubMed  CAS  Google Scholar 

  35. Goldman L, Cook F: The decline in ischemic heart disease mortality rates: an analysis of the comparative effective of medical interventions and changes in lifestyle. Ann Intern Med 1984, 101:825–836.

    PubMed  CAS  Google Scholar 

  36. Bobrie G, Chatellier G, Genes N, et al.: Cardiovascular prognosis of ‘masked hypertension’ detected by blood pressure self-measurement in elderly hypertensive patients. JAMA 2004, 291:1342–1349.

    Article  PubMed  CAS  Google Scholar 

  37. Mancia G, Facchetti R, Bombelli M, et al.: Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006, 47:846–853.

    Article  PubMed  CAS  Google Scholar 

  38. Egan BM, Papademetriou V, Wofford M, et al.: Metabolic syndrome and insulin resistance: contrasting views in patients with high normal blood pressure. Am J Hypertens 2005, 18:3–12.

    Article  PubMed  CAS  Google Scholar 

  39. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.

    Article  PubMed  CAS  Google Scholar 

  40. Appel LJ, Moore TJ, Obarzanek E, et al.: the DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997, 336:1117–1124.

    Article  PubMed  CAS  Google Scholar 

  41. Esposito K, Marella R, Ciotaola M, et al.: Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. JAMA 2004, 292:1440–1446.

    Article  PubMed  CAS  Google Scholar 

  42. Katzmarzyk PT, Church TS, Blair SN: Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004, 164:1092–1097.

    Article  PubMed  Google Scholar 

  43. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002: 346:393–403.

    Article  Google Scholar 

  44. Kjeldsen SE, Lyle PA, Tershakovec AM, et al.: Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opin Emerg Drugs 2005, 10:729–745.

    Article  PubMed  CAS  Google Scholar 

  45. Yavuz D, Koc M, Toprak A, et al.: Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003, 4:197–203.

    Article  PubMed  CAS  Google Scholar 

  46. Rosei EA, Rizzoni D, Muiesan ML, et al.: CENTRO (Candesartan atherosclerotic risk factors) study investigators: Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens 2005, 23:435–444.

    Article  PubMed  CAS  Google Scholar 

  47. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  48. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005, 366:895–906.

    Article  PubMed  Google Scholar 

  49. Jamerson KA, on behalf of the ACCOMPLISH investigators: Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. Presented at the American College of Cardiology Scientific Sessions. Chicago, IL; March 31, 2008.

  50. Materson BJ, Reda DJ, Preston RA, et al.: Response to a second single agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1995, 155:1757–1762.

    Article  PubMed  CAS  Google Scholar 

  51. Nissen SE, Tuzcu EM, Libby P, et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004, 292:2217–2226.

    Article  PubMed  CAS  Google Scholar 

  52. Wong ND, Pio JR, Franklin SS, et al.: Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003, 91:1421–1426.

    Article  PubMed  Google Scholar 

  53. Sever PS, Dahlof B, Poulter NR, et al.: ASCOT Investigators: Prevention of coronary and stroke events in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical University of South Carolina, 135 Rutledge Avenue, RT1104, Charleston, SC, 29425, USA

    Brent M. Egan

Authors
  1. Brent M. Egan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stevo Julius
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brent M. Egan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Egan, B.M., Julius, S. Prehypertension: Risk stratification and management considerations. Current Science Inc 10, 359–366 (2008). https://doi.org/10.1007/s11906-008-0068-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-008-0068-0

Keywords

  • Lifestyle Change
  • Antihypertensive Therapy
  • Candesartan
  • Cardiovascular Disease Risk
  • Candesartan Cilexetil